MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Trajectories of pain in newly diagnosed Parkinson’s disease

    J. Naisby, R. Lawson, B. Galna, L. Alcock, D. Burn, L. Rochester, A. Yarnall (Newcastle Upon Tyne, United Kingdom)

    Objective: To determine the frequency and stability of pain over time in a cohort of patients with early Parkinson’s disease (PD). Background: Pain is a…
  • MDS Virtual Congress 2020

    Frequency of Wearing-Off Symptoms in Parkinson’s disease Fluctuators: An on/off evaluation

    K. Perepezko, J. Hinkle, K. Mills, G. Pontone (Baltimore, MD, USA)

    Objective: To determine if the frequency of wearing-off symptoms in Parkinson’s disease (PD) patients who report fluctuations differs from patients without fluctuations. Background: Wearing-off, the…
  • MDS Virtual Congress 2020

    Difference in olfactory impairment between tremor dominant and akinetic rigid dominant Parkinson’s disease patients

    P. Solla, C. Masala, P. Raffaella, S. Dagostino, T. Ercoli, G. Defazio (Monserrato, Italy)

    Objective: To investigate difference in olfactory impairment between tremor dominant (TD) and akinetic rigid dominant (ARD) Parkinson’s disease patients. Background: PD can be classified in…
  • MDS Virtual Congress 2020

    Non-motor symptoms in Parkinson’s disease and the model of Braak

    H. You, F.X Lejeune, F. Danjou, S. Bekadar, J.C Corvol (Paris, France)

    Objective: We aimed to determine different subtypes of Parkinson’s disease (PD) patients using clinical data from the appearance chronology of their non-motor and motor symptoms…
  • MDS Virtual Congress 2020

    Biomarkers for Parkinson´s Disease with Reflex Tears Correlate with Disease Duration

    M. Lew, S. Janga, D. Feigenbaum, D. Freire, M. Edman, W. Mack, C. Okamoto, S. Hamm-Alvarez (Los Angeles, CA, USA)

    Objective: To determine if the protein composition of reflex tears differs in Parkinson’s disease (PD) patients stratified by disease duration compared to Healthy Controls (HC).…
  • MDS Virtual Congress 2020

    Non-mercaptalbumin as a potential biomarker of oxidative stress in Parkinson’s and PARK2 disease

    S. Ueno, T. Hatano, A. Okuzumi, S. Saiki, Y. Oji, A. Mori, T. Koinuma, M. Fujimaki, H. Takeshige-Amano, A. Kondo, N. Yoshikawa, T. Nojiri, M. Kurano, K. Yasukawa, Y. Yatomi, H. Ikeda, N. Hattori (Tokyo, Japan)

    Objective: To elucidate the oxidized albumin ratio, which is the redox ratio of human non-mercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in parkinsonism.…
  • MDS Virtual Congress 2020

    Maladaptive use of LD/CD tablets as painkillers causing Dopamine Dysregulation Syndrome in 4 patients of Advanced Parkinson’s Disease

    M. Gautam, K. Shukla, N. Sawal (Chandigarh, India)

    Objective: To study four cases of maladaptive use of levodopa/carbidopa (LD/CD) as painkillers causing Dopamine dysregulation syndrome (DDS) in Parkinson’s disease (PD) patient in a…
  • MDS Virtual Congress 2020

    Frequency of Impulse Control Disorders and Other Related Behaviors in People with Parkinson’s Disease

    G. Xavier-Souza, A. Mendoza, I. Alves, L. Almeida, G. Valença (Salvador, Brazil)

    Objective: To identify the frequency of impulse control disorders (ICDs) and other related behaviors (i.e. punding, hobbyism, walkabout and dopamine dysregulation syndrome) in people with…
  • MDS Virtual Congress 2020

    Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease

    C. Christine, R. Richardson, A. Van Laar, M. Thompson, K. Herbert, C. Li, G. Liang, E. Fine, P. Larson (San Francisco, CA, USA)

    Objective: To present preliminary 3-year data from the PD-1101 trial of VY-AADC01 for advanced Parkinson’s disease (PD) with motor fluctuations. Background: This 3-year phase 1b…
  • MDS Virtual Congress 2020

    Effects of Rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) Emotional Well-being Domain in Patients with Parkinson’s Disease (PD): A Post-Hoc Analysis of Clinical Trials in Japan

    N. Hattori, A. Takeda, Y. Hanya, T. Kitagawa, M. Arai, Y. Furusawa, H. Mochizuki, M. Nagai, R. Takahashi (Tokyo, Japan)

    Objective: To evaluate the direct and indirect effects of rasagiline on emotional well-being domain of the PDQ-39 in patients with PD by a post-hoc analysis…
  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley